Day One Biopharmaceuticals, Inc.於2018年11月在特拉華州註冊成立為一家有限責任公司。作為一家商業化階段的生物製藥公司,該公司專註於開發針對兒童和成人疾病的首創或同類最佳藥物。Day One採用搜索與開發戰略來識別、收購和推進藥物項目,其首個商業化產品是托沃拉非尼(tovorafenib)——一種口服、可穿透血腦屏障、高選擇性的II型RAF激酶抑製劑。
董事
名稱
職位
Jeremy Bender
Chief Executive Officer, President and Director
Julie Grant
Chair of the Board, Director and Co-Founder
Natalie Holles
Lead Independent Director
Dan Becker
Director
John Josey
Director
Michael Gladstone
Director
Saira Ramasastry
Director
股東
名稱
職位
Jeremy Bender
Chief Executive Officer, President and Director
Charles York II
Chief Operating Officer, Chief Financial Officer and Secretary